Johnson & Johnson的新肺癌治疗组合显示存活率比现有药物要好。 Johnson & Johnson's new lung cancer treatment combo shows better survival rates than current drugs.

Johnson & Johnson的MARIPOSA研究表明,将RYBREVANT和LAZCLUZE结合起来会大大降低肺癌患者对特定EGFR变异的抗药性,而仅与osimertinib相比,就显著降低了抗药性。 Johnson & Johnson's MARIPOSA study shows that combining RYBREVANT and LAZCLUZE significantly reduces resistance in lung cancer patients with specific EGFR mutations, compared to osimertinib alone. 这些结合提供了一种无法比拟的总体生存福利,预计超过4年,有可能通过预防抗药性改变疾病的走向。 The combination offers an unmatched overall survival benefit, projected to exceed four years, potentially changing the course of the disease by preventing resistance. 这种治疗在美国、欧洲和其他市场得到批准。 The treatment is approved in the U.S., Europe, and other markets.